Compounded GLP-1 prescriptions rise despite FDA enforcement, PeptideSciences goes dark, and Cleveland Clinic finds most patients avoid dramatic weight regain.
10 stories · Covering regulatory, research, industry
Today's peptide landscape reveals a stark enforcement paradox: the FDA has sent thousands of warning letters and cracked down on compounding operations, yet compounded GLP-1 prescriptions have actually increased since the semaglutide shortage ended — with 80% now containing supplemental ingredients to skirt regulations. The Washington Post editorial board added fuel to the fire, calling RFK Jr.'s simultaneous vaccine skepticism and peptide advocacy 'hypocritical quackery.' Meanwhile, the grey-market is shifting dramatically as PeptideSciences.com, once generating $7 million per month, voluntarily shut down under regulatory pressure. On the clinical side, a Cleveland Clinic real-world study of nearly 8,000 patients offered a surprise: most people who stop GLP-1 drugs don't experience the dramatic weight regain seen in controlled trials, with 45% maintaining or continuing to lose weight through treatment restarts and lifestyle changes.
Healthcare Brew reports that despite the FDA sending thousands of warning letters since September 2025, compounded semaglutide and tirzepatide prescriptions have increased since the semaglutide shortage ended in February 2025. About 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins to avoid being classified as exact copies of FDA-approved drugs.
The Washington Post editorial board published a sharp critique of Health Secretary Kennedy, arguing that his insistence on rigorous evidence for vaccines while simultaneously pushing the FDA to deregulate peptides with minimal human safety data represents a dangerous double standard in public health policy.
A Cleveland Clinic analysis of 7,938 adults who discontinued semaglutide or tirzepatide found that real-world outcomes are better than clinical trials suggested. Obesity patients regained just 0.5% of body weight on average after one year, and 45% either maintained or continued losing weight by restarting treatment, switching medications, or adopting lifestyle changes.
PeptideSciences, one of the largest grey-market research peptide vendors in the US reportedly generating over $7 million per month, voluntarily ceased all operations on March 6. The shutdown followed coordinated enforcement from the FDA, DOJ, and FBI targeting companies selling compounds like semaglutide and tirzepatide without pharmaceutical licensing.
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.
CMS confirmed that Medicare Part D beneficiaries will gain access to Wegovy and Zepbound for weight loss through the Medicare GLP-1 Bridge program starting July 2026 at a $50 monthly copayment, bridging to the full BALANCE Model launching in Medicare Part D in January 2027.
CNBC reports that within six months of starting a GLP-1 medication, households reduce grocery spending by 5.3% and fast-food spending by 8%. Dinner traffic has fallen 6% among regular users, with ultra-processed food spending down 10%. Food companies are racing to develop protein- and fiber-rich 'GLP-1 friendly' products.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.
Novo Nordisk signed a deal worth up to $2.1 billion with Vivtex Corporation, an MIT spinoff co-founded by Bob Langer, to develop next-generation oral biologic medicines for obesity and diabetes. Vivtex's AI-driven platform screens thousands of drug delivery formulations per day with near-perfect correlation to human intestinal absorption.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.